Η XM δεν παρέχει υπηρεσίες σε κατοίκους των Ηνωμένων Πολιτειών Αμερικής.

Η XM δεν παρέχει υπηρεσίες σε κατοίκους των Ηνωμένων Πολιτειών Αμερικής.
S
S

Sanofi

Ειδήσεις

Reuters - 3 ημέρες πριν

Probiotics maker Seed Health explores $1 billion sale, sources say

Probiotics maker Seed Health explores $1 billion sale, sources say By Abigail Summerville and Anirban Sen June 12 (Reuters) - The owners of Seed Health, one of the few profitable U.S. biotechnology startups, are exploring a sale of the probiotics maker that could value it at more than $1 billion, according to people familiar with the matter. Seed, which is owned by its founders and co-chief executives Ara Katz and Raja Dhir, as well as venture capital investors, is soliciting acquisition offers
S
Reuters - 5 ημέρες πριν

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V
Reuters - 5 ημέρες πριν

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

UPDATE 1-GSK asks to appeal Delaware ruling allowing Zantac cases to go forward Recasts headline, paragraphs 1-4 with appeal petition By Brendan Pierson June 10 (Reuters) - GSK GSK.L and other drugmakers on Monday asked a Delaware court for permission to appeal a ruling allowing more than 70,000 lawsuits claiming that heartburn drug Zantac causes cancer to go forward.
G
P
S
Reuters - 5 ημέρες πριν

Latest trial over Zantac cancer claims called off as plaintiff drops case

Latest trial over Zantac cancer claims called off as plaintiff drops case By Brendan Pierson June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's GSK.L discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced. GSK said in a statement that it did not settle with the woman, Eugenia Kasza.
G
P
S
Reuters - 6 ημέρες πριν

Moderna rises as COVID/flu combo vaccine shows superiority over separate shots in trial

BUZZ-Moderna rises as COVID/flu combo vaccine shows superiority over separate shots in trial ** Shares of Moderna MRNA.O rise 1.81% to $153.75 premarket ** Co says its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response when compared to separate shots in a late-stage trial ** The combination vacci
G
S
Reuters - 6 ημέρες πριν

Moderna COVID/flu combo vaccine superior to separate shots in trial

Moderna COVID/flu combo vaccine superior to separate shots in trial By Patrick Wingrove June 10 (Reuters) - Moderna MRNA.O said on Monday its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response in adults aged 50 and over when compared to separate shots against the viruses in a late-stage trial. In the study, the combination using messenger RNA technology generated greater antibodies than currently marketed traditional flu vaccines and Moderna's
S
Reuters - 1 εβδομάδα πριν

What to know about bird flu in dairy cows and the risk to humans

EXPLAINER-What to know about bird flu in dairy cows and the risk to humans Adds new details on affected states in paragraphs 1-2, details on a fatal case in Mexico By Julie Steenhuysen CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total number of affected states, which have been encouraged to ramp up testing efforts at the request of government officials.
G
S
Reuters - 1 εβδομάδα πριν

EuroAPI appoints mediator to help restructure pile of debt, shares drop

UPDATE 1-EuroAPI appoints mediator to help restructure pile of debt, shares drop Updates with market reaction segment By Nathan Vifflin June 7 (Reuters) - French pharmaceutical supplier EuroAPI EAPI.PA has engaged a third-party mediator, known as a mandataire ad hoc, to handle financing discussions with creditors as it struggles to serve a growing pile of debt.
S
Reuters - 2 εβδομάδες πριν

Column: Will Zantac ruling make Delaware a mass torts magnet?

Column: Will Zantac ruling make Delaware a mass torts magnet? The opinions expressed here are those of the author, a columnist for Reuters. By Alison Frankel June 3 (Reuters) - If you are mass torts lawyer, you should be paying attention to a trend that has emerged in litigation over the discontinued heartburn medication Zantac. On Friday, as my Reuters colleague Brendan Pierson reported , a Delaware Superior Court judge ruled that nearly 75,000 lawsuits alleging that Zantac causes cancer can mo
G
P
S
Reuters - 2 εβδομάδες πριν

Sanofi Says Sarclisa Is First Anti-Cd38 To Improve Progression-Free Survival For Diagnosed Transplant-Ineligible Multiple Myeloma In Phase 3

BRIEF-Sanofi Says Sarclisa Is First Anti-Cd38 To Improve Progression-Free Survival For Diagnosed Transplant-Ineligible Multiple Myeloma In Phase 3 June 3 (Reuters) - Sanofi SA SASY.PA : REG-PRESS RELEASE: ASCO: SARCLISA IS FIRST ANTI-CD38 TO SIGNIFICANTLY IMPROVE PROGRESSION-FREE SURVIVAL IN COMBINATION WITH VRD FOR NEWLY DIAGNOSED TRANSPLANT-INELI
S
Reuters - 2 εβδομάδες πριν

Investors prescribe harsh medicine for GSK’s boss

BREAKINGVIEWS-Investors prescribe harsh medicine for GSK’s boss The author is a Reuters Breakingviews columnist. The opinions expressed are her own. Refiles to change ambiguous ‘them’ in fifth paragraph to ‘investors’. By Yawen Chen LONDON, June 3 (Reuters Breakingviews) - GSK GSK.L investors are having a panic attack. Jittery shareholders of the $93 billion British drugmaker on Monday wiped $9 billion off its value after a U.S.
A
G
S
Reuters - 2 εβδομάδες πριν

Deutsche Post Group - Dhl Supply Chain Partners with Sanofi

BRIEF-Deutsche Post Group - Dhl Supply Chain Partners with Sanofi June 3 (Reuters) - DEUTSCHE POST AG DHLn.DE : DHL SUPPLY CHAIN EXPANDS PHARMA LOGISTICS OPERATIONS IN FRANCE DHL SUPPLY CHAIN HAS EXPANDED ITS SPECIALIZED LOGISTICS SERVICES FOR THE LIFE SCIENCES AND HEALTHCARE SECTOR IN FRANCE THROUGH A LONG-TERM STRATEGIC PARTNERSHIP WITH SANOFI DH
S
Reuters - 2 εβδομάδες πριν

GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed

UPDATE 2-GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed Updates shares and adds more analysts in paragraphs 7-11 By Yadarisa Shabong and Maggie Fick June 3 (Reuters) - Shares of GSK GSK.L dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer, to go forward, in a blow for the British drugmaker.
G
P
S
Reuters - 2 εβδομάδες πριν

Sanofi Pushes Ahead With 20 Bln Euros Consumer Healthcare Spin-Off - FT

BRIEF-Sanofi Pushes Ahead With 20 Bln Euros Consumer Healthcare Spin-Off - FT June 2 (Reuters) - SANOFI PUSHES AHEAD WITH €20BN CONSUMER HEALTHCARE SPIN-OFF - FT GOLDMAN SACHS, MORGAN STANLEY WILL WORK WITH BNP PARIBAS & BANK OF AMERICA ON SALE; POTENTIAL FLOAT EXPECTED TO TAKE PLACE AS SOON AS END OF YEAR - FT Source text: https://on.ft.com/4bXj
S
Reuters - 2 εβδομάδες πριν

Delaware judge lets more than 70,000 Zantac lawsuits go forward

UPDATE 2-Delaware judge lets more than 70,000 Zantac lawsuits go forward Adds detail from opinion in paragraphs 3-4 By Brendan Pierson June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer. The ruling on Friday by Judge Vivian Medinilla of the Delaware Superior Court in Wilmington is a setback for former Zantac makers GSK GSK.L , Pfizer PFE.N
G
P
S
Reuters - 2 εβδομάδες πριν

Delaware judge lets more than 70,000 Zantac lawsuits go forward

Delaware judge lets more than 70,000 Zantac lawsuits go forward June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer. The ruling on Friday by Judge Vivian Medinilla of the Delaware Superior Court in Wilmington is a setback for former Zantac makers GSK GSK.L , Pfizer PFE.N , Sanofi SASY.PA and Boehringer Ingelheim, which had argued that the e
G
P
S
Reuters - 2 εβδομάδες πριν

EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review

UPDATE 1-EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review Adds details from EMA disclosure and background throughout May 31 (Reuters) - Sanofi SASY.PA and partner Regeneron Pharmaceuticals REGN.O have secured the European regulator's backing for use of Dupixent in patients with a chronic lung disease even as the U.S. Food and Drug Administration (FDA) extended its review.
R
S
Reuters - 2 εβδομάδες πριν

EMA Says Valneva's Chikungunya Vaccine Receives Positive CHMP Opinion

BRIEF-EMA Says Valneva's Chikungunya Vaccine Receives Positive CHMP Opinion May 31 (Reuters) - EMA: EMA SAYS IXCHIQ (CHIKUNGUNYA VACCINE (LIVE)) RECEIVED POSITIVE CHMP OPINION EMA:CHMP GAVE RECOMMENDATION FOR CONDITIONAL MARKETING AUTHORISATION FOR DURVEQTIX(FIDANACOGENE ELAPARVOVEC), GENE THERAPY TREATMENT FOR HAEMOPHILIA EMA SAYS CHMP HAS RESTART
P
S
Reuters - 2 εβδομάδες πριν

FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung'

FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung' May 31 (Reuters) - French drugmaker Sanofi SASY.PA and its partner Regeneron REGN.O said on Friday the U.S. Food and Drug Administration (FDA) requested additional analyses on the efficacy of Dupixent as an add-on treatment in certain patients 'smoker's lung', or COPD.
R
S
Reuters - 2 εβδομάδες πριν

Sanofi: Dupixent Recommended For EU Approval By CHMP For Patients With COPD

BRIEF-Sanofi: Dupixent Recommended For EU Approval By CHMP For Patients With COPD May 31 (Reuters) - Sanofi SA SASY.PA : DUPIXENT RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT PATIENTS WITH COPD RECOMMENDATION FOR ADULTS WITH UNCONTROLLED COPD WITH RAISED BLOOD EOSINOPHILS BASED ON DATA FROM TWO LANDMARK PHASE 3 TRIALS EUROPEAN COMMISSION IS EXP
S

Όροι

Δημοφιλή περιουσιακά στοιχεία

Δήλωση αποποίησης ευθύνης: Οι οντότητες του ομίλου XM Group παρέχουν υπηρεσίες σε βάση εκτέλεσης μόνο και η πρόσβαση στην ηλεκτρονική πλατφόρμα συναλλαγών μας που επιτρέπει στον ενδιαφερόμενο να δει ή/και να χρησιμοποιήσει το περιεχόμενο που είναι διαθέσιμο στην ιστοσελίδα μας ή μέσω αυτής, δε διαφοροποιεί ούτε επεκτείνει αυτές τις υπηρεσίες πέραν αυτού ούτε προορίζεται για κάτι τέτοιο. Η εν λόγω πρόσβαση και χρήση υπόκεινται σε: (i) Όρους και προϋποθέσεις, (ii) Προειδοποιήσεις κινδύνου και (iii) Πλήρη δήλωση αποποίησης ευθύνης. Ως εκ τούτου, το περιεχόμενο αυτό παρέχεται μόνο ως γενική πληροφόρηση. Λάβετε ιδιαιτέρως υπόψη σας ότι τα περιεχόμενα της ηλεκτρονικής πλατφόρμας συναλλαγών μας δεν αποτελούν παρότρυνση, ούτε προσφορά για να προβείτε σε οποιεσδήποτε συναλλαγές στις χρηματοπιστωτικές αγορές. Η πραγματοποίηση συναλλαγών στις χρηματοπιστωτικές αγορές ενέχει σημαντικό κίνδυνο για το κεφάλαιό σας.

Όλο το υλικό που δημοσιεύεται στην ηλεκτρονική πλατφόρμα συναλλαγών μας προορίζεται για εκπαιδευτικούς/ενημερωτικούς σκοπούς μόνο και δεν περιέχει, ούτε θα πρέπει να θεωρηθεί ότι περιέχει συμβουλές και συστάσεις χρηματοοικονομικές ή σε σχέση με φόρο επενδύσεων και την πραγματοποίηση συναλλαγών, ούτε αρχείο των τιμών διαπραγμάτευσής μας ούτε και προσφορά ή παρότρυνση για συναλλαγή οποιωνδήποτε χρηματοπιστωτικών μέσων ή ανεπιθύμητες προς εσάς προωθητικές ενέργειες.

Οποιοδήποτε περιεχόμενο τρίτων, καθώς και περιεχόμενο που εκπονείται από την ΧΜ, όπως απόψεις, ειδήσεις, έρευνα, αναλύσεις, τιμές, άλλες πληροφορίες ή σύνδεσμοι προς ιστότοπους τρίτων το οποίο περιέχεται σε αυτήν την ιστοσελίδα παρέχεται «ως έχει», ως γενικός σχολιασμός της αγοράς και δεν αποτελεί επενδυτική συμβουλή. Στον βαθμό που οποιοδήποτε περιεχόμενο ερμηνεύεται ως επενδυτική έρευνα, πρέπει να λάβετε υπόψη και να αποδεχτείτε ότι το περιεχόμενο δεν προοριζόταν και δεν έχει προετοιμαστεί σύμφωνα με τις νομικές απαιτήσεις που αποσκοπούν στην προώθηση της ανεξαρτησίας της επενδυτικής έρευνας και ως εκ τούτου, θα πρέπει να θεωρηθεί ως επικοινωνία μάρκετινγκ σύμφωνα με τους σχετικούς νόμους και κανονισμούς. Παρακαλούμε εξασφαλίστε ότι έχετε διαβάσει και κατανοήσει τη Γνωστοποίησή μας περί Μη ανεξάρτητης επενδυτικής έρευνας και την Προειδοποίηση ρίσκου όσον αφορά τις παραπάνω πληροφορίες, τις οποίες μπορείτε να βρείτε εδώ.

Προειδοποίηση ρίσκου: Τα κεφάλαιά σας κινδυνεύουν. Τα προϊόντα με μόχλευση ενδέχεται να μην είναι κατάλληλα για όλους. Παρακαλούμε λάβετε υπόψη σας τη Γνωστοποίηση ρίσκου.